Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal

COPENHAGEN (Reuters) - Danish drugmaker Lundbeck said on Friday it had agreed to buy Prexton Therapeutics, which has drug candidate foliglurax in phase II testing for treatment of Parkinson's disease.